SCHEMBL2054560

SCHEMBL2054560

COCCNC(=O)[C@H]1c2ccccc2C(=O)N(Cc2ccc(Cl)cc2)[C@H]1c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 1.00
TP53 P04637 3/20 1.00
ALDH1A1 P00352 3/20 0.69
MAPT P10636 2/20 0.69
KDM4E B2RXH2 1/20 0.69
HTT P42858 1/20 0.69
TSHR P16473 1/20 0.59
NPSR1 Q6W5P4 4/20 0.56
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.49
ALOX15 P16050 1/20 0.47
KCNA5 P22460 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GLA P06280 1/20 0.45
CASP1 P29466 1/20 0.45
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2098874 1.00 MDM2 (1.00) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL2054563 1.00 MDM2 (1.00) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL29921819 1.00 MDM2 (1.00) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL2054559 1.00 MDM2 (1.00) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL2054562 1.00 MDM2 (1.00) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL29931625 0.92 MDM2 (0.85) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL2098559 0.92 MDM2 (0.85) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL23295997 0.88 MDM2 (0.79) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL29921785 0.88 MDM2 (0.79) MDM2TP53ALDH1A1MAPTKDM4E
SCHEMBL2098547 0.88 MDM2 (0.79) MDM2TP53ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163744-B2 Tetrahydro-isoquinolin-1-ones for the treatment of cancer NEXUSPHARMA, INC. (US) 2012-04-24 US disclosed
US-8163744-B2 Tetrahydro-isoquinolin-1-ones for the treatment of cancer NEXUSPHARMA, INC. (US) 2012-04-24 US disclosed
US-8163744-B2 Tetrahydro-isoquinolin-1-ones for the treatment of cancer NEXUSPHARMA, INC. (US) 2012-04-24 US disclosed
US-20090068144-A1 TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER NEXUSPHARMA INC. 2009-03-12 US disclosed
US-20090068144-A1 TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER NEXUSPHARMA INC. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068144-A1 TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER ING2, HMGB2, NOTCH2 MDM2 9/4885TP53 26/4885ALDH1A1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.